Status:
WITHDRAWN
Focal Therapy for Prostate Cancer
Lead Sponsor:
University of Maryland, Baltimore
Collaborating Sponsors:
University of Maryland, College Park
Conditions:
Prostatic Neoplasms
Prostate Cancer
Eligibility:
MALE
45+ years
Phase:
PHASE2
Brief Summary
Prostate cancer is the most common solid organ cancer among men and is the second leading cause of cancer death. In 2013 about 238,590 men will be diagnosed with prostate cancer and 29,720 men will di...
Detailed Description
Prostate cancer is a lethal disease for \~11% of the men who are diagnosed with it. Early detection of prostate cancer using the PSA blood test can detect cancer a decade or more before it would have ...
Eligibility Criteria
Inclusion
- Male
- Age \>44
- Low risk Prostate Cancer (PSA \<10, Gleason 6)
- Low-volume intermediate risk prostate cancer (PSA \<15, Gleason 3+4=7)
- Organ confined disease
Exclusion
- Metastatic Disease
- Palpable disease bilaterally
- Locally advanced disease either by digital rectal exam or MRI
- PSA \>10 (for age \<75)
- PSA \>15
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01802307
Start Date
February 1 2013
End Date
March 1 2018
Last Update
May 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland School of Medicine
Baltimore, Maryland, United States, 21201